血管内皮抑素协同肿瘤特异性DC-T细胞的抗肿瘤效应
Antitumor effect of endostatin synergized with tumor special DC-T cellular therapy

DOI: 10.6040/j.issn.1671-7554.0.2014.977

Keywords: 细胞免疫治疗,肿瘤微环境,血管内皮抑素,血管新生,肺肿瘤,
Cellular therapy,Angiogenesis,Lung neoplasm,Endostatin,Tumor microenvironment

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Keibel A, Singh V, Sharma MC. Inflammation, microenvironment, and the immune system in cancer progression[J]. Curr Pharm Des, 2009, 15(17): 1949-1955.
[2]	Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883-899.
[3]	Nair S, Boczkowski D, Moeller B, et al. Synergy between tumor immunotherapy and antiangiogenic therapy[J]. Blood, 2003, 102(3): 964 -971.
[4]	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
[5]	Sharma P, Wagner K, Wolchok JD, et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps[J]. Nat Rev Cancer, 2011, 11(11): 805-812.
[6]	Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer[J]. Proc Natl Acad Sci U S A, 2008, 105(35): 12643-12644.
[7]	Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know[J]. Nat Rev Clin Oncol, 2011, 8(10): 577-585.
[8]	Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis[J]. Nat Rev Clin Oncol, 2011, 8(4): 210-221.
[9]	Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies[J]. Cancer Res, 2009, 69(6): 2514-2522.
[10]	Griffioen AW. Anti-angiogenesis: making the tumor vulnerable to the immune system[J]. Cancer Immunol Immunother, 2008, 57(10): 1553-1558.
[11]	De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?[J]. Nat Rev Clin Oncol, 2011, 8(7):393-404.
[12]	Vasievich EA, Huang L. The suppressive tumor microenvironment: a challenge in cancer immunotherapy[J]. Mol Pharm, 2011, 8(3): 635-641.
[13]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[14]	Sonpavde G, Agarwal N, Choueiri TK, et al. Recent advances in immunotherapy for the treatment of prostate cancer[J]. Expert Opin Biol Ther, 2011, 11(8): 997-1009.
[15]	Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients[J]. Clin Cancer Res, 2009, 15(6): 2148-2157.
[16]	Teicher BA. Antiangiogenic agents and targets: a perspective[J]. Biochem Pharmacol, 2011, 81(1): 6-12.
[17]	Schoenfeld J, Jinushi M, Nakazaki Y, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis[J]. Cancer Res, 2010, 70(24): 10150-10160.

Full-Text